Bills · S 3788
REPORTED· 119TH CONGRESS
Senate BillS 3788Supply chainManufacturing
CLEAR LABELS Act
INTRO FEB 5· LAST ACTION JUL 27
READING
8MIN
COSPONSORS
12
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 3 / 8Introduced
In Committee
Reported
Passed Senate
Passed House
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill is important because it directly addresses concerns about the transparency and safety of the global drug supply chain. Many medications today have complex origins, with different ingredients and manufacturing steps occurring in various countries. Currently, a drug label might only show the name of the company that distributes the final product, leaving consumers unaware of where the actual medicinal ingredients were made.
If this bill becomes law, consumers would have clear, accessible information about the full journey of their medications, from the original source of key ingredients to the final packaged product. This increased transparency could help patients and healthcare providers make more informed choices. It could also make it easier to track down the source of quality issues or counterfeit drugs, potentially improving public health and safety. Without this bill, the current system of drug labeling would continue, leaving many questions about drug origins unanswered for the average person.
KEY PROVISIONS
5AI-extractedPROVISION 01
Requires labels for finished drug products to include the name, location, and unique identifier of the manufacturer, packer, or distributor, or provide a scannable link to an online portal with this data.
This ensures clear identification of the immediate entity responsible for the drug package.
PROVISION 02
Mandates that labels for active pharmaceutical ingredients (APIs) include the name, location, and unique identifier of their original manufacturer.
This provides critical transparency for the core medicinal components of drugs.
PROVISION 03
Requires finished drug product labels to include the name, location, and unique identifier of the original manufacturer of each active pharmaceutical ingredient and the original manufacturer of the finished drug product itself.
This provides comprehensive traceability of all key stages of a drug's production, from raw material to final product.
PROVISION 04
Requires that all mandated labeling information, including that accessed via electronic links, also be made available in paper copy upon request.
This ensures accessibility for individuals who may not have access to or prefer not to use electronic means.
PROVISION 05
Exempts finished drug products that comply with this act's labeling requirements from certain customs country-of-origin marking rules.
This streamlines international trade and prevents redundant labeling for compliant products.
SPONSORSHIP
1 + 12
R· Florida
YRS IN OFFICE
7
BILLS LED
184
COSPONSOR BREAKDOWNBIPARTISAN · 17%
DEM 1 REP 11 IND 0
ACTION TIMELINE
9 EVENTSJUL 27
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
JUL 27
Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.
JUL 22
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
MAR 19
Committee on Health, Education, Labor, and Pensions. Hearings held.
BILL INFO
TypeSenate Bill
NumberS 3788
Congress119th
StatusReported
IntroducedFeb 5, 2026
Last actionJul 27, 2026
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
REPORTED· 119TH CONGRESS · HEALTH, EDUCATION, LABOR, AND PENSIONS COMMITTEE · INTRODUCED FEB 5, 2026
Senate BillS 3788Supply chainManufacturing
CLEAR LABELS Act
INTRODUCED FEB 5, 2026· LAST ACTION JUL 27, 2026
PASSAGE CHANCES
—%
READING
8 min
COSPONSORS
12
COMPLEXITY
Moderate
